Keya Medical Secures $100

Keya Medical, an international medical technology company, has secured $100,000 in a recent funding round from investors.

This capital infusion marks a significant step for the company, which specializes in developing deep learning-based medical devices aimed at enhancing disease diagnosis and treatment.

The investment will support Keya Medical's mission to bring advanced AI-driven solutions to the healthcare market.

The company's flagship product is DEEPVESSEL FFR, a deep-learning-based CT FFR analysis tool.

This innovative software medical device utilizes deep learning technology to perform a non-invasive physiological functional assessment of the coronary arteries using coronary computed tomography angiography (CCTA).

DEEPVESSEL FFR has achieved notable regulatory milestones, being FDA-cleared, CE-marked, and NMPA-approved, underscoring its clinical validation and readiness for widespread adoption in medical practice.

The $100,000 in secured investment capital will be strategically deployed to fuel Keya Medical's ongoing growth initiatives.

The company plans to allocate the funds towards advancing its research and development pipeline, particularly in refining and expanding its deep learning algorithms for new diagnostic applications.

Additionally, a portion of the capital will be directed towards scaling its market reach, enabling broader access to its cutting-edge diagnostic tools for healthcare providers globally.

This funding round highlights investor confidence in Keya Medical's innovative approach to leveraging artificial intelligence for critical medical diagnostics.

The investment is expected to accelerate the company's trajectory, enabling it to further solidify its position as a leader in AI-powered medical technology and continue its expansion into new markets, ultimately benefiting patient care worldwide.